Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mavrilimumab - CSL/Kiniksa Pharmaceuticals

Drug Profile

Mavrilimumab - CSL/Kiniksa Pharmaceuticals

Alternative Names: Anti-GM-CSFR monoclonal antibody - MedImmune; CAM-3001; KPL-301

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zenyth Therapeutics
  • Developer Kiniksa Pharmaceuticals; MedImmune
  • Class Anti-infectives; Anti-inflammatories; Antirheumatics; Cardiovascular therapies; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists; Granulocyte-macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant cell arteritis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cardiovascular disorders

Highest Development Phases

  • Phase II Giant cell arteritis
  • Phase I Cardiovascular disorders
  • Discontinued Inflammation; Rheumatoid arthritis; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 01 Nov 2022 Mavrilimumab - CSL/Kiniksa Pharmaceuticals is available for licensing as of 01 Nov 2022. www.kiniksa.com 9372285
  • 19 Aug 2022 Phase-I clinical trials in Cardiovascular disorders in USA (unspecified route), as of August 2022 (Kiniksa Pharmaceuticals pipeline, August 2022)
  • 01 Jun 2022 Pharmacodynamics data from preclinical studies in Giant cell arteritis at the 23rd Annual Congress of the European League Against Rheumatism (EULAR-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top